Clinical Trial

Confirmatory Study of Govorestat in CMT-SORD

Withdrawn Phase 3
View on ClinicalTrials.gov →
Why the trial stopped
The study was withdrawn prior to enrollment as the sponsor decided not to proceed with study initiation.
Summary
This study is designed to assess the long-term efficacy and clinical benefit of AT-007 in patients with CMT-SORD. This randomized, double-blind study will assess the effect of govorestat compared to placebo in patients with CMT-SORD for up to 36 months.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-22.
Status change: Not Yet Recruiting → Withdrawn 2026-05-27
Trial Details
NCT Number NCT07191912
Lead Sponsor Applied Therapeutics, Inc.
Conditions Charcot-Marie-Tooth Disease With Sorbitol Dehydrogenase Deficiency (CMT-SORD)
Start Date 2026-05
Primary Completion 2028-10 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-29